Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest radiation therapy Stories

2013-12-05 23:31:06

RiboMed Biotechnologies, Inc. and NuvOx Pharma today jointly announced that they have entered into a collaborative agreement that will utilize RiboMed’s epigenetic biomarker test, GliomaSTRAT™, to characterize tumors from brain cancer patients and correlate response to NuvOx’s new drug, NVX-108 in the treatment of Glioblastoma multiforme (GBM). Carlsbad, CA and Tucson, AZ (PRWEB) December 05, 2013 RiboMed Biotechnologies, Inc. and NuvOx Pharma today jointly announced that they have...

2013-12-05 08:28:54

PRINCETON, N.J., Dec. 5, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator...

2013-12-03 23:26:13

RSSearch™ Patient Registry study highlights include demographics, SRS/SBRT treatment patterns and brain and liver metastases outcomes. (PRWEB) December 03, 2013 The Radiosurgery Society® (the RSS), a non-profit organization of medical professionals dedicated to advancing the science and clinical practice of stereotactic body radiotherapy (SBRT) and radiosurgery (SRS), announced that the first report from the RSSearch™ Patient Registry, a multi-institutional, observational...

2013-12-03 16:25:11

GLENWOOD, Ill., Dec. 3, 2013 /PRNewswire/ -- Landauer, Inc. (NYSE: LDR), a recognized leader in personal and environmental radiation measurement and monitoring, outsourced medical physics services and high quality medical consumable accessories, announced today that its Board of Directors declared, at its meeting on December 3, 2013, a regular quarterly cash dividend of $0.55 per share for the first quarter of fiscal 2014. The dividend will be paid on January 6, 2014, to shareholders...

2013-11-27 12:24:15

Monaco 5 radiation therapy treatment planning system unites capabilities in a single system ATLANTA, Nov. 27, 2013 /PRNewswire/ -- Monaco® 5, the latest version of Elekta's Monaco treatment planning system has received 510(k) clearance from the US Food & Drug Administration, making it available for purchase and use in the United States. "Monaco 5 consolidates the best of Elekta's treatment planning solutions into one system, increasing confidence and clinical versatility for...

2013-11-27 08:25:31

Results of Review¹ by Harley Street and University College Hospital London Presented in Online Edition of 'Radiotherapy and Oncology' (Green Journal) LONDON, Nov. 27, 2013 /PRNewswire/ -- Treating early stage non-small-cell lung cancer (NSCLC) patients with advanced radiotherapy appears to be a viable alternative to surgery, according to researchers who carried out a retrospective comparative study sponsored by the London-based South East Cancer Oncology Group. A review was...

2013-11-26 16:24:20

LISBON, Portugal, Nov. 26, 2013 /PRNewswire/ -- Leading oncology centers have reported on advances in stereotactic radiosurgery (SRS) and stereotactic ablative radiotherapy (SABR) treatments at the first Varian Edge(TM) Radiosurgery Symposium, held at the Champalimaud Centre for the Unknown in Lisbon, Portugal. Experts from leading centers of excellence around the world presented details of the latest in advanced treatment techniques to an audience of over 110 industry professionals....

2013-11-25 08:27:50

More than 700 CyberKnife® and TomoTherapy® Systems Have Treated More Than Half a Million Patients Worldwide SUNNYVALE, Calif., Nov. 25, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today continued momentum in global adoption of its CyberKnife® and TomoTherapy® Systems. Accuray has expanded its installed base to more than 700 systems worldwide which have been used to treat more than half a million patients, further positioning the company as a leader in...

2013-11-20 12:28:46

CORALVILLE, Iowa, Nov. 20, 2013 /PRNewswire/ -- CIVCO Medical Solutions advances the standard in real-time planning with FDA 510(k) clearance of the EX3 Stepper for Low Dose Rate (LDR) and High Dose Rate (HDR) ultrasound-guided brachytherapy for prostate cancer detection and treatment. (Logo: http://photos.prnewswire.com/prnh/20110419/AQ85801LOGO) LDR prostate brachytherapy involves internal radiotherapy where tiny radioactive 'seeds' are delivered through a needle and are...

2013-11-18 23:21:18

Woman Remains Cancer-Free 13 Years after Participating in Breast Cancer Study Royal Oak, MI (PRWEB) November 18, 2013 Beaumont Hospital in Royal Oak, Mich. presented updated research results at this year’s American Society for Radiation Oncology conference. The outcomes showed that APBI, and traditional whole-breast irradiation are comparable at 10 years. While radiation therapy has traditionally been delivered using whole breast irradiation, APBI is a proven alternative that shortens...